Advancing Cxbladder as standard of care - Clinical Study

Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today announces it is advancing its clinical evidence generation program with LOBSTER (Longitudinal Bladder Cancer Study for Tumor Recurrence) – a multi-centre observational clinical study focused on demonstrating the clinical utility of Cxbladder Monitor for surveillance of recurrent urothelial cancer against the current American Urological Association (AUA) standard of care targeting existing guidelines language for greater inclusion of Cxbladder.

Pacific Edge has contracted two sites, has initiated one site to date, and expects to enrol the first patient in LOBSTER this quarter.

See attachment for full press release.

---

Announcement PDF